Despite a significant run in the valuation of InterMune (NASDAQ:ITMN) on the back of positive Phase III ASCEND data in March, I have not seen much of an attempt to put definitive numbers around what this means for the market potential of Esbriet starting in 2015. I won't go into much analysis on approvability in this article, as I believe the market correctly assumes approval.
In this analysis I will:
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|